Speeches & presentations

Search through our archive of speeches and presentations from conferences and events.

Filter by

  • ViiV Meet the Management, London

    David Redfern, Chairman ViiV Healthcare and Deborah Waterhouse, CEO ViiV Healthcare along with members of the ViiV Healthcare leadership team hosted a ViiV Healthcare Investor Event on Monday 10 December in London. The event included presentations from David, Deborah, Dr Kimberly Smith Global Research & Medical Strategy, Eric Dube Head of North America and Dr John Pottage Chief Scientific & Medical Officer and was followed by a Q&A session.

  • Dr Hal Barron, GSK

    Citi 2018 Global Healthcare Conference, New York

    Hal Barron, Chief Scientific Officer and President, R&D hosted a fireside chat at the Citi 2018 Global Healthcare Conference held in New York City on Wednesday 5 December, in which he provided an overview of GSK’s R&D priorities and progress made during 2018.

    Analyst webcast
  • Analyst call on agreement to acquire TESARO

    On Monday, 3 December 2018, GSK announced an agreement to acquire TESARO, an oncology-focused company based in the US. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer, Dr Hal Barron, Chief Scientific Officer and President R&D, and Luke Miels, President, GSK Global Pharmaceuticals.

  • Evercore ISI HealthConX Conference, Boston

    Deborah Waterhouse, CEO, and Dr Kimberly Smith, Head of Global Research and Medical Strategy, ViiV Healthcare, hosted a fireside chat at the Evercore ISI HealthConX Conference held in Boston, Massachusetts on Wednesday 28 November, during which they provided an overview of ViiV’s priorities and progress made during 2018.

    Analyst webcast
  • Investor and Analyst call on GSK’165 aGM-CSF data presented at ACR

    On Tuesday, 23 October 2018, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of efficacy and safety data on GSK3196165, GSK's anti-GM-CSF antibody in development for Rheumatoid Arthritis at the 2018 American College of Rheumatology (ACR). The call also featured participation from an external expert in rheumatology and GSK’s Medicine Development Lead for GSK’165.

  • Brian McNamara

    Consumer Healthcare investor event, New Jersey

    Brian McNamara, CEO GSK Consumer Healthcare, and members of his leadership team hosted an investor event to review the Consumer Healthcare business. This event included a tour of our Shopper Science, Consumer Sensory and R&D labs, as well as presentations from Brian McNamara, Marc Speichert, SVP Digital and Richard Slater, SVP R&D, followed by a Q&A session.

  • Emma Walmsley GSK CEO

    CECP CEO Investor Forum

    Emma Walmsley, CEO, spoke at CECP’s CEO Investor Forum on Thursday 20 September 2018 about the steps we are taking to build trust – one of our three long-term priorities – and drive sustainable business performance.

    Analyst webcast
  • Emma Walmsley GSK CEO

    Bank of America Merrill Lynch Global Healthcare Conference, London

    Emma Walmsley, CEO, gave a presentation at the Bank of America Merrill Lynch Global Healthcare Conference in London on Thursday 13 September 2018 in which she provided an overview of GSK’s priorities and progress made during 2018.

    Analyst webcast
  • David Redfern

    GEMINI Results of HIV 2 Drug Regimen Investor & Analyst Update

    On Tuesday, 24 July 2018, GSK hosted an investor conference call following the presentation of the full set of scientific and clinical data on GSK’s 2 drug regimen of dolutegravir plus lamiviudine (GEMINI studies) in treatment naïve HIV patients at the 22nd International AIDS Conference.

    The call was hosted by David Redfern, GSK Chief of Strategy and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO of ViiV Healthcare, John Pottage, Chief Scientific & Medical Officer of ViiV Healthcare, and Kimberly Smith, VP Global Research & Medical Strategy of ViiV Healthcare.

  • David Redfern

    Goldman Sachs 39th Annual Healthcare Conference, California

    David Redfern, Chief Strategy Officer, hosted a fireside chat at the Goldman Sachs 39th Annual Healthcare Conference in Rancho Palos Verdes, California on Wednesday 13 June, in which he provided an overview of GSK’s priorities and progress made during 2018.

    Analyst webcast
  • David Redfern

    Jefferies 2018 Healthcare Conference, New York City

    David Redfern, Chief Strategy Officer, hosted a fireside chat at the Jefferies 2018 Healthcare Conference in New York City on Wednesday 6 June, in which he provided an overview of GSK’s priorities and progress made during 2018.

    Please access the webcast using Google Chrome. 

    Analyst webcast
  • Emma, Simon and Brian

    Consumer Healthcare Update, London

    On Tuesday, 27 March 2018, GSK reached an agreement with Novartis to acquire full ownership of the Consumer Healthcare business. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer and Brian McNamara, CEO, Consumer Healthcare.

    Analyst webcast
  • Emma Walmsley GSK CEO

    36th annual JP Morgan Healthcare Conference, San Francisco, USA

    Emma Walmsley, CEO, gave a presentation at the 36th annual JP Morgan Healthcare Conference in San Francisco about our business outlook, as well as our latest product approvals and advances in our pipeline.

    Analyst webcast
  • Luke Miels, Axel Hoos

    GSK Oncology Investor & Analyst Update

    On Tuesday, 12 December 2017, GSK hosted an investor conference call following the presentation of scientific and clinical data on GSK2857916, GSK's anti-BCMA (B-cell Maturation Antigen) antibody-drug conjugate presented at the 59th American Society of Hematology (ASH) annual meeting.

    The call was hosted by Luke Miels, President, GSK Global Pharmaceuticals and Axel Hoos, SVP and Therapy Area Head of Oncology R&D. The call also featured participation from an external expert in multiple myeloma.

  • Dr. Axel Hoos, SVP

    Citi Global Healthcare Conference, New York

    Axel Hoos, SVP – Oncology R&D, participated in a fireside chat at the Citi Global Healthcare Conference on December 7 in New York.

    Analyst webcast
  • David Redfern

    Evercore conference, Boston

    David Redfern, Chief Strategy Officer and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO of ViiV Healthcare and Kim Smith, Vice President, Global Medical Strategy, ViiV Healthcare, participated in a fireside chat at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference in Boston on Thursday, November 30.

    Analyst webcast
  • Brian McNamara

    Consumer Healthcare investor event

    Brian McNamara, CEO GSK Consumer Healthcare, and members of his leadership team hosted an investor event to review the Consumer Healthcare business. This event included a tour of our Shopper Science and Consumer Sensory labs, as well as presentations from Brian McNamara and Richard Slater, SVP, R&D Consumer Healthcare, followed by a Q&A session.

  • Emma Walmsley and Simon Dingemans

    Investor event, London 2017

    The investor event outlined the Group’s key priorities including presentations from Emma Walmsley, CEO, and Simon Dingemans, CFO.

    Watch the webcast on YouTube
  • Dr. Axel Hoos, SVP

    Cowen 37th Annual Healthcare Conference

    Axel Hoos, SVP – Oncology R&D, gave a presentation at the Cowen and Company 37th Annual Health Care Conference  in Boston. Axel provided an overview of GSK’s Oncology strategy and pipeline.

    Register for the webcast
  • ViiV Healthcare Chairman David Redfern, CEO Dominique Limet and Chief Scientific and Medical Officer John Pottage

    Investor event at CROI 2017, Seattle

    ViiV Healthcare Chairman David Redfern, CEO Dominique Limet and Chief Scientific and Medical Officer John Pottage, hosted an investor event following the presentation of the SWORD Phase III data at the Conference on Retroviral and Opportunistic Infections.